Click on the protein name for more information about the protein.
The Score column is the predicted score of interaction between the two proteins
Click on the Evidence link to view a breakdown of the information about the predicted interaction.
| Key | |
|---|---|
| Module Score | Databases |
![]() | Where interaction is observed in another database a link is provided: |
| Protein 1 (?) | Protein 2 (?) | Name of Protein 2 | Module Scores (?) | Scores (?) | Evidence (?) | Database (?) | |||
|---|---|---|---|---|---|---|---|---|---|
![]() | ![]() | ![]() | ![]() | ||||||
| CSK | STAT6 | STAT6: Signal transducer and activator of transcription 6 | 1.53E3 | Evidence | |||||
| CSK | TYK2 | TYK2: Non-receptor tyrosine-protein kinase TYK2 | 1.17E3 | Evidence | |||||
| CSK | VAV1 | VAV1, VAV: Proto-oncogene vav | 1.17E3 | Evidence | |||||
| CSK | SYK | SYK: Tyrosine-protein kinase SYK | 720.0 | Evidence | |||||
| CSK | JAK2 | JAK2: Tyrosine-protein kinase JAK2 | 674.0 | Evidence | |||||
| CSK | BTK | BTK, AGMX1, ATK, BPK: Tyrosine-protein kinase BTK | 549.0 | Evidence | |||||
| CSK | NCK1 | NCK1, NCK: Cytoplasmic protein NCK1 | 549.0 | Evidence | |||||
| CSK | ZAP70 | ZAP70: Uncharacterized protein ZAP70 | 497.0 | Evidence | |||||
| CSK | CRKL | CRKL: Crk-like protein | 408.0 | Evidence | |||||
| CSK | NCK2 | NCK2: Cytoplasmic protein NCK2 | 408.0 | Evidence | |||||
| CSK | SH3BP2 | SH3BP2: Uncharacterized protein SH3BP2 | 370.0 | Evidence | |||||
| CSK | LCP2 | LCP2: Lymphocyte cytosolic protein 2 | 364.0 | Evidence | |||||
| CSK | STAT5B | STAT5B: Signal transducer and activator of transcription 5B | 306.0 | Evidence | |||||
| CSK | CSF1R | CSF1R, FMS: Macrophage colony-stimulating factor 1 receptor precursor | 305.0 | Evidence | |||||
| CSK | STAT5A | STAT5A, STAT5: Signal transducer and activator of transcription 5A | 301.0 | Evidence | |||||
| CSK | APS | SH2B2, APS: SH2B adapter protein 2 | 268.0 | Evidence | |||||
| CSK | HCLS1 | HCLS1, HS1: Hematopoietic lineage cell-specific protein | 226.0 | Evidence | |||||
| CSK | WAS | WAS, IMD2: Wiskott-Aldrich syndrome protein | 226.0 | Evidence | |||||
| CSK | WASPIP | N/A | 194.0 | Evidence | |||||
| CSK | SH2D2A | SH2D2A, SCAP, TSAD, VRAP: SH2 domain-containing protein 2A | 181.0 | Evidence | |||||
| CSK | SRC | SRC, SRC1: Proto-oncogene tyrosine-protein kinase Src | 181.0 | Evidence |
|
||||
| CSK | MAP4K1 | MAP4K1, HPK1: Mitogen-activated protein kinase kinase kinase kinase 1 | 165.0 | Evidence | |||||
| CSK | TXK | TXK, PTK4: Tyrosine-protein kinase TXK | 162.0 | Evidence | |||||
| CSK | KIT | KIT: Mast/stem cell growth factor receptor precursor | 149.0 | Evidence | |||||
| CSK | FLT1 | FLT1, FLT, FRT: Vascular endothelial growth factor receptor 1 precursor | 134.0 | Evidence | |||||
| CSK | PDGFRB | PDGFRB: Beta-type platelet-derived growth factor receptor precursor | 134.0 | Evidence | |||||
| CSK | PTPN6 | PTPN6, HCP, PTP1C: Tyrosine-protein phosphatase non-receptor type 6 | 119.0 | Evidence | |||||
| CSK | LNK | SH2B3, LNK: SH2B adapter protein 3 | 119.0 | Evidence | |||||
| CSK | ABL1 | ABL1, ABL, JTK7: Proto-oncogene tyrosine-protein kinase ABL1 | 109.0 | Evidence | |||||
| CSK | STAT3 | 106.0 | Evidence | ||||||
| CSK | RASA1 | RASA1, RASA: Ras GTPase-activating protein 1 | 106.0 | Evidence |
|
||||
| CSK | ITK | ITK, EMT, LYK: Tyrosine-protein kinase ITK/TSK | 106.0 | Evidence | |||||
| CSK | PTK2B | PTK2B, FAK2, PYK2, RAFTK: Protein tyrosine kinase 2 beta | 106.0 | Evidence | |||||
| CSK | STAT1 | STAT1: Signal transducer and activator of transcription 1-alpha/beta | 104.0 | Evidence | |||||
| CSK | TEC | TEC, PSCTK4: Tyrosine-protein kinase Tec | 98.20 | Evidence | |||||
| CSK | AXL | AXL, UFO: Tyrosine-protein kinase receptor UFO precursor | 89.20 | Evidence | |||||
| CSK | KHDRBS1 | KHDRBS1, SAM68: KH domain-containing, RNA-binding, signal transduction-associate | 87.80 | Evidence | |||||
| CSK | RET | RET: Proto-oncogene tyrosine-protein kinase receptor ret precursor | 79.90 | Evidence | |||||
| CSK | CBL | CBL, CBL2, RNF55: E3 ubiquitin-protein ligase CBL | 78.20 | Evidence | O | ||||
| CSK | PIK3R2 | PIK3R2: Phosphatidylinositol 3-kinase regulatory subunit beta | 71.10 | Evidence | |||||
| CSK | RAF1 | RAF1, RAF: RAF proto-oncogene serine/threonine-protein kinase | 64.00 | Evidence | |||||
| CSK | GRAP | GRAP: GRB2-related adapter protein | 61.00 | Evidence | |||||
| CSK | CBLC | CBLC, CBL3, RNF57: Signal transduction protein CBL-C | 58.60 | Evidence | |||||
| CSK | GRB10 | N/A | 56.20 | Evidence | |||||
| CSK | PCBP1 | PCBP1: Poly(rC)-binding protein 1 | 53.40 | Evidence | |||||
| CSK | IGF1R | IGF1R: Insulin-like growth factor 1 receptor precursor | 52.50 | Evidence |
O
|
||||
| CSK | KDR | KDR, FLK1: Vascular endothelial growth factor receptor 2 precursor | 52.50 | Evidence | |||||
| CSK | EPHB2 | EPHB2, DRT, EPHT3, EPTH3, ERK, HEK5, TYRO5: Ephrin type-B receptor 2 precursor | 47.30 | Evidence | |||||
| CSK | INSR | INSR: Insulin receptor precursor | 47.30 | Evidence |
|
||||
| CSK | TEK | TEK, TIE2: Angiopoietin-1 receptor precursor | 47.20 | Evidence | |||||
| CSK | PCBP2 | PCBP2: Poly(rC)-binding protein 2 | 45.90 | Evidence | |||||
| CSK | SH2D1A | SH2D1A, DSHP, SAP: SH2 domain-containing protein 1A | 44.70 | Evidence | |||||
| CSK | DOK1 | DOK1: Docking protein 1 | 44.40 | Evidence |
|
||||
| CSK | PIK3CG | PIK3CG: Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma i | 42.00 | Evidence | |||||
| CSK | CD2AP | CD2AP: CD2-associated protein | 42.00 | Evidence | |||||
| CSK | NMT1 | NMT1, NMT: Glycylpeptide N-tetradecanoyltransferase 1 | 35.00 | Evidence | |||||
| CSK | NRBP1 | NRBP1, BCON3, NRBP: Nuclear receptor-binding protein | 33.90 | Evidence | |||||
| CSK | CD22 | CD22, SIGLEC2: B-cell receptor CD22 precursor | 30.90 | Evidence | |||||
| CSK | CD79A | CD79A, IGA, MB1: B-cell antigen receptor complex-associated protein alpha-chain | 30.90 | Evidence | |||||
| CSK | ACP1 | ACP1: Low molecular weight phosphotyrosine protein phosphatase | 25.00 | Evidence | |||||
| CSK | SLAMF1 | SLAMF1, SLAM: Signaling lymphocytic activation molecule precursor | 24.90 | Evidence | |||||
| CSK | BRDG1 | STAP1, BRDG1: Signal-transducing adaptor protein 1 | 24.10 | Evidence | |||||
| CSK | SRMS | SRMS, C20orf148: Tyrosine-protein kinase Srms | 24.10 | Evidence | |||||
| CSK | HD | HD, IT15: Huntingtin | 23.60 | Evidence | |||||
| CSK | PASK | PASK, KIAA0135: PAS domain-containing serine/threonine-protein kinase | 22.80 | Evidence | |||||
| CSK | HLA-F | HLA-F, HLA-5.4, HLAF: HLA class I histocompatibility antigen, alpha chain F prec | 21.00 | Evidence | |||||
| CSK | IL2RB | IL2RB: Interleukin-2 receptor subunit beta precursor | 18.40 | Evidence | |||||
| CSK | CSF2RB | CSF2RB, IL3RB, IL5RB: Cytokine receptor common beta chain precursor | 18.40 | Evidence | |||||
| CSK | CDC25A | CDC25A: M-phase inducer phosphatase 1 | 17.60 | Evidence | |||||
| CSK | PRKAA1 | N/A | 17.30 | Evidence | |||||
| CSK | EIF4G2 | EIF4G2, DAP5, OK/SW-cl.75: Eukaryotic translation initiation factor 4 gamma 2 | 16.30 | Evidence | |||||
| CSK | SNCA | SNCA, NACP, PARK1: Alpha-synuclein | 15.00 | Evidence | |||||
| CSK | NEDD9 | NEDD9, CASL: Enhancer of filamentation 1 | 13.40 | Evidence | |||||
| CSK | PDPK1 | PDPK1, PDK1: 3-phosphoinositide-dependent protein kinase 1 | 13.40 | Evidence | |||||
| CSK | ELMO1 | N/A | 13.40 | Evidence | |||||
| CSK | PRKCQ | PRKCQ, PRKCT: Protein kinase C theta type | 12.40 | Evidence | |||||
| CSK | PRKCE | PRKCE, PKCE: Protein kinase C epsilon type | 11.80 | Evidence | |||||
| CSK | STAG2 | STAG2, SA2: Cohesin subunit SA-2 | 11.70 | Evidence | |||||
| CSK | HNRPK | N/A | 11.70 | Evidence |
|
||||
| CSK | PTPN2 | PTPN2, PTPT: Tyrosine-protein phosphatase non-receptor type 2 | 11.60 | Evidence | |||||
| CSK | PRKCG | PRKCG, PKCG: Protein kinase C gamma type | 11.60 | Evidence | |||||
| CSK | PECAM1 | PECAM1: Platelet endothelial cell adhesion molecule precursor | 11.40 | Evidence |
|
||||
| CSK | ACTG1 | ACTB: Actin, cytoplasmic 1 | 10.80 | Evidence | |||||
| CSK | TGFBR1 | TGFBR1: TGF-beta receptor type-1 precursor | 10.70 | Evidence | |||||
| CSK | TYRO3 | TYRO3, BYK, DTK, RSE, SKY: Tyrosine-protein kinase receptor TYRO3 precursor | 10.40 | Evidence | |||||
| CSK | HSP90AA1 | Hsp89-alpha-delta-N | 10.30 | Evidence | |||||
| CSK | PLD2 | PLD2: Phospholipase D2 | 10.00 | Evidence |
|
||||
| CSK | MAPK3 | MAPK3, ERK1, PRKM3: Mitogen-activated protein kinase 3 | 10.00 | Evidence | |||||
| CSK | ADAM15 | ADAM15, MDC15: ADAM 15 precursor | 9.92 | Evidence | |||||
| CSK | CD79B | CD79B, B29, IGB: B-cell antigen receptor complex-associated protein beta-chain p | 9.92 | Evidence | |||||
| CSK | PTPRC | PTPRC, RP11-553K8.4-001, hCG_1811178: Protein tyrosine phosphatase, receptor typ | 9.92 | Evidence | |||||
| CSK | FCGR2B | FCGR2B, CD32, FCG2, IGFR2: Low affinity immunoglobulin gamma Fc region receptor | 9.92 | Evidence | |||||
| CSK | TRPV4 | TRPV4, VRL2, VROAC: Transient receptor potential cation channel subfamily V memb | 9.92 | Evidence | |||||
| CSK | SMAD2 | SMAD2, MADH2, MADR2: Mothers against decapentaplegic homolog 2 | 9.17 | Evidence | |||||
| CSK | DAB2 | DAB2, DOC2: Disabled homolog 2 | 8.86 | Evidence |
|
||||
| CSK | PRKCA | PRKCA, PKCA, PRKACA: Protein kinase C alpha type | 8.86 | Evidence | |||||
| CSK | TNKS2 | TNKS2, PARP5B, TANK2, TNKL: Tankyrase-2 | 8.81 | Evidence | |||||
| CSK | EIF4G3 | EIF4G3: Eukaryotic translation initiation factor 4 gamma 3 | 8.00 | Evidence | |||||
| CSK | DAPP1 | N/A | 7.93 | Evidence | |||||
| CSK | UBAP2L | UBAP2L, KIAA0144, NICE4: Ubiquitin-associated protein 2-like | 7.93 | Evidence | |||||
| CSK | AKAP12 | AKAP12, AKAP250: A-kinase anchor protein 12 | 7.59 | Evidence | |||||
| CSK | HNRPK | HNRPK, HNRNPK: Heterogeneous nuclear ribonucleoprotein K | 7.59 | Evidence | |||||
| CSK | SCAP2 | SKAP2, PRAP, RA70, SAPS, SCAP2, SKAP55R: Src kinase-associated phosphoprotein 2 | 7.57 | Evidence | |||||
| CSK | FASLG | FASLG, APT1LG1, FASL, TNFSF6: Tumor necrosis factor ligand superfamily member 6 | 7.40 | Evidence | |||||
| CSK | CD5 | CD5, LEU1: T-cell surface glycoprotein CD5 precursor | 7.40 | Evidence | |||||
| CSK | YWHAB | YWHAB: 14-3-3 protein beta/alpha | 7.10 | Evidence | |||||
| CSK | PPP1R12A | PPP1R12A, MBS, MYPT1: Protein phosphatase 1 regulatory subunit 12A | 7.10 | Evidence | |||||
| CSK | PRKX | PRKX, PKX1: Serine/threonine-protein kinase PRKX | 6.78 | Evidence | |||||
| CSK | MTMR1 | MTMR1: Myotubularin-related protein 1 | 6.78 | Evidence | |||||
| CSK | IKBKG | IKBKG, FIP3, NEMO: NF-kappa-B essential modulator | 6.71 | Evidence | |||||
| CSK | EPOR | EPOR: Erythropoietin receptor precursor | 6.52 | Evidence | |||||
| CSK | SH3BP1 | SH3BP1: SH3 domain-binding protein 1 | 6.11 | Evidence | |||||
| CSK | PPP1R8 | N/A | 6.01 | Evidence | |||||
| CSK | ITGB4 | N/A | 5.88 | Evidence | |||||
| CSK | BCAR1 | BCAR1, CAS, CRKAS: Breast cancer anti-estrogen resistance protein 1 | 5.50 | Evidence | |||||
| CSK | DUSP2 | DUSP2, PAC1: Dual specificity protein phosphatase 2 | 5.33 | Evidence | |||||
| CSK | LYN | LYN: Tyrosine-protein kinase Lyn | 5.22 | Evidence |
|
||||
| CSK | BFAR | BFAR, BAR, RNF47: Bifunctional apoptosis regulator | 4.80 | Evidence | |||||
| CSK | FCER1G | FCER1G: High affinity immunoglobulin epsilon receptor subunit gamma precursor | 4.80 | Evidence | |||||
| CSK | SYNCRIP | SYNCRIP, HNRPQ, NSAP1: Heterogeneous nuclear ribonucleoprotein Q | 4.77 | Evidence | |||||
| CSK | TCF3 | TCF3, E2A, ITF1: Transcription factor E2-alpha | 4.77 | Evidence | |||||
| CSK | NULL | Ig lambda chain V-I region EPS | 4.68 | Evidence | |||||
| CSK | DNM1 | DNM1, DNM: Dynamin-1 | 4.68 | Evidence | |||||
| CSK | IGHE | IGHE: Ig epsilon chain C region | 4.68 | Evidence | |||||
| CSK | PPP3R1 | PPP3R1, CNA2, CNB: Calcineurin subunit B isoform 1 | 4.51 | Evidence | |||||
| CSK | S100A4 | S100A4, CAPL, MTS1: Protein S100-A4 | 4.51 | Evidence | |||||
| CSK | PLAUR | PLAUR, MO3, UPAR: Urokinase plasminogen activator surface receptor precursor | 4.48 | Evidence | |||||
| CSK | HSPD1 | 4.23 | Evidence | ||||||
| CSK | CASP3 | CASP3, CPP32: Caspase-3 precursor | 4.23 | Evidence | |||||
| CSK | EVL | N/A | 4.23 | Evidence | |||||
| CSK | PTPN11 | N/A | 4.23 | Evidence | |||||
| CSK | CD19 | N/A | 4.06 | Evidence | |||||
| CSK | GRIA3 | GRIA3, GLUR3, GLURC: Glutamate receptor 3 precursor | 4.01 | Evidence | |||||
| CSK | SMAD3 | SMAD3, MADH3: Mothers against decapentaplegic homolog 3 | 3.85 | Evidence | |||||
| CSK | CREBBP | CREBBP, CBP: CREB-binding protein | 3.85 | Evidence |
O
|
||||
| CSK | CD36 | CD36, GP3B, GP4: Platelet glycoprotein 4 | 3.69 | Evidence | |||||
| CSK | DHX16 | DHX16, DBP2, DDX16, KIAA0577: Putative pre-mRNA-splicing factor ATP-dependent RN | 3.64 | Evidence | |||||
| CSK | GTF2B | GTF2B, TF2B, TFIIB: Transcription initiation factor IIB | 3.64 | Evidence | |||||
| CSK | ZNF217 | ZNF217, ZABC1: Zinc finger protein 217 | 3.64 | Evidence | |||||
| CSK | BLNK | BLNK, BASH, SLP65: B-cell linker protein | 3.52 | Evidence | |||||
| CSK | KPNA2 | KPNA2, RCH1, SRP1: Importin subunit alpha-2 | 3.47 | Evidence | |||||
| CSK | AQP2 | AQP2: Aquaporin-2 | 3.18 | Evidence | |||||
| CSK | JAK1 | 3.15 | Evidence | ||||||
| CSK | FGR | FGR, SRC2: Proto-oncogene tyrosine-protein kinase FGR | 3.15 | Evidence |
|
||||
| CSK | GJB1 | GJB1, CX32: Gap junction beta-1 protein | 3.08 | Evidence | |||||
| CSK | CD48 | CD48, BCM1, BLAST1: CD48 antigen precursor | 3.01 | Evidence | |||||
| CSK | ZYX | ZYX: Zyxin | 2.94 | Evidence | |||||
| CSK | SLA | SLA, SLAP, SLAP1: SRC-like-adapter | 2.84 | Evidence | |||||
| CSK | CTLA4 | CTLA4, CD152: Cytotoxic T-lymphocyte protein 4 precursor | 2.77 | Evidence | |||||
| CSK | AGTR1 | AGTR1, AGTR1A, AGTR1B, AT2R1, AT2R1B: Type-1 angiotensin II receptor | 2.65 | Evidence | |||||
| CSK | TXN | TXN, TRDX, TRX, TRX1: Thioredoxin | 2.63 | Evidence | |||||
| CSK | CASP9 | CASP9, MCH6: Caspase-9 precursor | 2.54 | Evidence | |||||
| CSK | MATK | 2.54 | Evidence | ||||||
| CSK | CAV1 | CAV1, CAV: Caveolin-1 | 2.48 | Evidence |
O
|
||||
| CSK | CBLB | CBLB, RNF56, Nbla00127: E3 ubiquitin-protein ligase CBL-B | 2.36 | Evidence | |||||
| CSK | IREB2 | IREB2: Iron-responsive element-binding protein 2 | 2.34 | Evidence | |||||
| CSK | GCN5L2 | GCN5L2, GCN5, HGCN5: General control of amino acid synthesis protein 5-like 2 | 2.33 | Evidence | |||||
| CSK | CASP7 | N/A | 2.28 | Evidence | |||||
| CSK | PDE8B | PDE8B: High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodies | 2.28 | Evidence | |||||
| CSK | GIT2 | N/A | 2.28 | Evidence | |||||
| CSK | BCR | N/A | 2.28 | Evidence | |||||
| CSK | DOK3 | N/A | 2.17 | Evidence |
|
||||
| CSK | SLC4A1 | SLC4A1, AE1, DI, EPB3: Band 3 anion transport protein | 2.14 | Evidence | |||||
| CSK | SHC1 | SHC1, RP11-307C12.1-001, hCG_1997126: SHC | 2.10 | Evidence |
|
||||
| CSK | LCK | LCK: Proto-oncogene tyrosine-protein kinase LCK | 2.1 | Evidence |
|
||||
| CSK | CMTM6 | CMTM6, CKLFSF6: CKLF-like MARVEL transmembrane domain-containing protein 6 | 2.0 | Evidence | |||||
| CSK | FCGR2A | FCGR2A: Fc of IgG, low affinity IIa, receptor | 1.98 | Evidence | |||||
| CSK | GRAP2 | GRAP2, GADS, GRB2L, GRID: GRB2-related adapter protein 2 | 1.88 | Evidence | |||||
| CSK | HCK | N/A | 1.88 | Evidence |
|
||||
| CSK | SIGLEC5 | SIGLEC5, CD33L2, OBBP2: Sialic acid-binding Ig-like lectin 5 precursor | 1.76 | Evidence | |||||
| CSK | ACTB | ACTG1, ACTB, ACTG: Actin, cytoplasmic 2 | 1.63 | Evidence | |||||
| CSK | STAT2 | STAT2: Signal transducer and activator of transcription 2 | 1.57 | Evidence | |||||
| CSK | PIK3CD | PIK3CD: Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta i | 1.57 | Evidence | |||||
| CSK | SMAD1 | SMAD1, BSP1, MADH1, MADR1: Mothers against decapentaplegic homolog 1 | 1.53 | Evidence | |||||
| CSK | DOCK2 | DOCK2, KIAA0209: Dedicator of cytokinesis protein 2 | 1.41 | Evidence | |||||
| CSK | LCP1 | LCP1, PLS2: Plastin-2 | 1.41 | Evidence | |||||
| CSK | CXorf9 | N/A | 1.41 | Evidence | |||||
| CSK | FNBP1 | N/A | 1.41 | Evidence | |||||
| CSK | EHD1 | EHD1, PAST, CDABP0131, PAST1: EH domain-containing protein 1 | 1.41 | Evidence | |||||
| CSK | PLCG1 | PLCG1, PLC1: 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase gamma-1 | 1.30 | Evidence | |||||
| CSK | TESK1 | TESK1: Dual specificity testis-specific protein kinase 1 | 1.30 | Evidence | |||||
| CSK | CTBP1 | CTBP1, CTBP: C-terminal-binding protein 1 | 1.23 | Evidence | |||||
| CSK | LSP1 | 1.17 | Evidence | ||||||
| CSK | FXYD5 | FXYD5, DYSAD, HSPC113, IWU1, UNQ2561/PRO6241: FXYD domain-containing ion transpo | 1.17 | Evidence | |||||
| CSK | STAT4 | STAT4: Signal transducer and activator of transcription 4 | 1.15 | Evidence | |||||
| CSK | MATK | MATK, CTK, HYL: Megakaryocyte-associated tyrosine-protein kinase | 1.13 | Evidence | |||||
| CSK | SLA2 | SLA2, C20orf156, SLAP2: Src-like-adapter 2 | 1.13 | Evidence | |||||
| CSK | ABL2 | ABL2, ABLL, ARG: Tyrosine-protein kinase ABL2 | 1.13 | Evidence | |||||
| CSK | SOCS3 | SOCS3, CIS3, SSI3: Suppressor of cytokine signaling 3 | 1.04 | Evidence | |||||
| CSK | HLA-C | HLA-C, HLAC: HLA class I histocompatibility antigen, Cw-7 alpha chain precursor | 1.03 | Evidence | |||||
| CSK | HLA-G | HLA-G, HLA-6.0, HLAG: HLA class I histocompatibility antigen, alpha chain G prec | 1.03 | Evidence | |||||
| CSK | PLEK | PLEK, P47: Pleckstrin | 1.03 | Evidence | |||||
| CSK | HLA-A | HLA-A, HLAA: HLA class I histocompatibility antigen, A-3 alpha chain precursor | 1.03 | Evidence | |||||
| CSK | HLA-B | HLA-B, HLAB: HLA class I histocompatibility antigen, B-7 alpha chain precursor | 1.03 | Evidence | |||||
| CSK | FYN | FYN: Proto-oncogene tyrosine-protein kinase Fyn | 1.01 | Evidence |
O
|
||||
| CSK | GRB2 | GRB2, ASH: Growth factor receptor-bound protein 2 | 1.01 | Evidence | |||||